EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Glycoprotein L–deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E–restricted CD8+ T cells that protect against SIV

Scott G Hansen, John B Schell iD, Emily E Marshall, Sohita Ojha, Shana Feltham, David Morrow, Colette M Hughes, Roxanne M Gilbride, Julia C Ford, Hilary C Cleveland-Rubeor, Matthew R McArdle, Travis Whitmer und 12 weitere

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Scott G Hansen und 23 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Cytomegalovirus, Simian Immunodeficiency Virus, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Strain 68-1 rhesus CMV (RhCMV) vectors induce immune responses that mediate early, complete replication arrest of SIV infection in ∼60% of vaccinated rhesus macaques (RMs). This unique efficacy depends on the ability of these vectors to elicit effector memory (EM)-biased CD8+ T cells recognizing SIV peptides presented by MHC-E, rather than MHC-Ia. These efficacious responses still occurred when spread of the 68-1 vector was impaired by deletion of the viral anti-host intrinsic immunity factor phosphoprotein 71 (pp71), but efficacy was lost with a more stringent attenuation strategy based on destabilization of Rh108, the ortholog of the essential human CMV (HCMV) transcription factor UL79 that is required for late viral gene expression. Although unable to produce infectious progeny (ie single-cycle infection), Rh108-deficient vectors elicited durable, high frequency, EM-biased, SIV-specific CD8+ T-cell responses in RMs, but these responses were MHC-Ia–restricted and therefore non-efficacious. Here, we tested a different single-cycle attenuation strategy based on deletion (Δ) of the glycoprotein L (gL) that is essential for viral entry but allows for late gene expression and viral assembly. ΔgL 68-1 RhCMV/SIV vectors, grown on gL-complementing fibroblasts, were robustly immunogenic at doses above 105 PFU, generating high frequency, EM-biased, SIV-specific CD8+ T-cell responses that were also unconventionally restricted, including the MHC-E restriction associated with efficacy. Indeed, these single-cycle vectors manifested replication arrest efficacy in 70% of vaccinated RMs, further linking MHC-E restriction with efficacy, and demonstrating that 68-1 RhCMV/SIV efficacy does not require vector dissemination within the host.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesCytomegalovirusSimian Immunodeficiency VirusHistocompatibility Antigens Class IGenetic VectorsSimian Acquired Immunodeficiency SyndromeSAIDS VaccinesViral Envelope ProteinsAnimalsMacaca mulattaHumans

Stichwörter der Autor:innen

CD8+ T cellsCMV vectorsHIV vaccineMHC-E

Substanzen

Histocompatibility Antigens Class ISAIDS VaccinesViral Envelope Proteins

Autor:innen und Institutionen

  • Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
  • AIDS and Cancer Virus Program, SAIC Frederick, Inc., Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

ORCID-Profile: John B Schell, Louis J Picker

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • ODCDC CDC HHS
  • Bill and Melinda Gates Foundation
  • National Institute of Allergy and Infectious Diseases
  • L.J.P.
  • National Institutes of Health, Office of the Director

Zitieren

APA

Hansen, S. G., Schell, J. B., Marshall, E. E., Ojha, S., Feltham, S., Morrow, D., Hughes, C. M., Gilbride, R. M., Ford, J. C., Cleveland-Rubeor, H. C., McArdle, M. R., Whitmer, T., Barber-Axthelm, A., Bochart, R., Smedley, J., Oswald, K., Fast, R., Shoemaker, R., Kosmider, E., …, & Picker, L. J. (2025). Glycoprotein L–deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E–restricted CD8+ T cells that protect against SIV. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf104

Vancouver

Hansen SG, Schell JB, Marshall EE, Ojha S, Feltham S, Morrow D, et al. Glycoprotein L–deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E–restricted CD8+ T cells that protect against SIV. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf104

BibTeX
@article{Hansen2025,
  author = {Hansen, Scott G and Schell, John B and Marshall, Emily E and Ojha, Sohita and Feltham, Shana and Morrow, David and Hughes, Colette M and Gilbride, Roxanne M and Ford, Julia C and Cleveland-Rubeor, Hilary C and McArdle, Matthew R and Whitmer, Travis and Barber-Axthelm, Aaron and Bochart, Rachelle and Smedley, Jeremy and Oswald, Kelli and Fast, Randy and Shoemaker, Rebecca and Kosmider, Ewelina and Edlefsen, Paul T and Lifson, Jeffrey D and Malouli, Daniel and Früh, Klaus and Picker, Louis J},
  title = {Glycoprotein L–deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E–restricted CD8+ T cells that protect against SIV},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf104}
}
Kostenlos starten →